Clinical trial
Continuing Treatment With Pegasys and Copegus
NCT00336518 · Májbetegekért Alapítvány, Other · Unknown status
Key facts
| NCT number | NCT00336518 |
|---|---|
| Title | Continuing Treatment With Pegasys and Copegus |
| Official title | Efficacy and Safety of Continuing for a Total of 48 or Prolonging for a Total of 72 Weeks of Combined Treatment of Patients Receiving Pegasys and Copegus Who Are Biochemical Responders But Virological Non-Responders at Week 12 or Week 24 |
| Lead sponsor | Májbetegekért Alapítvány, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C |
| Intervention type | Drug |
| Interventions | peginterferon alfa-2a, ribavirin |
| Enrollment | 100 |
| Start date | Jun 1, 2006 |
| Completion | Jul 1, 2009 |
| First posted | Jun 13, 2006 |
| Last update posted | Jun 13, 2006 |
| Countries | Hungary |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: